Premium pharmaceutical and nutraceutical grade botanical derivatives optimized for LDL reduction and metabolic balance formulations.
The international cardiovascular health sector is undergoing a profound transition. Global health authorities, including the European Society of Cardiology (ESC) and the American Heart Association (AHA), have progressively tightened the target thresholds for low-density lipoprotein cholesterol (LDL-C), particularly for high-risk populations. While synthetic statins and PCSK9 monoclonal antibodies remain the standard of care in acute clinical settings, there is an accelerating consumer and clinical demand for natural, botanical, and bio-identical lipid-lowering compounds with fewer side effects.
As a premier ODM LDL Cholesterol Factory and Contract Manufacturing organization, Chengdu Chenlv Herb Co., Ltd. (Chenlv Herb) stands at the nexus of biochemical innovation and scalable industrial botany. Founded in 2012, Chenlv Herb integrates molecular research and development, smart production, and strict global quality control to engineer high-potency, standardized natural compounds that regulate lipid profiles. By focusing on targeted biochemical pathways, we provide global pharmaceutical, nutraceutical, and clinical health brand owners with the exact active ingredients and OEM solutions required to address the modern cardiovascular epidemic.
Typical raw material sourcing focusing purely on chemical specifications fails to optimize therapeutic efficacy. Modern clinical brands require pathway-specific bioavailability. Chenlv Herb specializes in extracting specialized bile acids (such as Taurochenodeoxycholic Acid and Cholic Acid) and phytocompounds (like Berberine and Hesperidin) that directly downregulate cholesterol absorption, activate AMPK, and modulate the cellular LDLR recycling mechanism, ensuring measurable clinical outcomes.
Our engineering pathways target multiple biological routes to safely lower systemic LDL-C without the side-effect profiles of high-dose chemical interventions.
Our phytocompounds, specifically berberine-related alkaloids, act as natural PCSK9 modulators. By preventing PCSK9 from binding to Low-Density Lipoprotein Receptors (LDLR) on hepatocytes, we increase the recycling of receptors back to the cell surface, accelerating the clearance of circulating LDL-C from the blood plasma.
Utilizing high-purity bile acids such as Taurochenodeoxycholic Acid (TCDCA) and Sodium Dehydrocholate, our solutions optimize the farnesoid X receptor (FXR) pathways. Inhibiting bile acid reabsorption in the ileum forces the liver to convert endogenous cholesterol into new bile acids, lowering systemic cholesterol reserves.
Through active compounds like hesperidin and fenugreek saponins, our formulations stimulate the AMP-activated protein kinase (AMPK) pathway. This downregulates HMG-CoA reductase (the primary enzyme responsible for liver cholesterol synthesis) and ACC, preventing intracellular lipogenesis.
The future of lipid management lies in multi-target synergy. Rather than relying on a single high-dose pathway (which often leads to muscle fatigue or liver stress, as seen with statins), modern cardiovascular products leverage combination matrix formulations. Our R&D roadmap focuses on developing co-crystalized and nanostructured delivery systems, combining phytosterols, highly active flavonoids (like Hesperidin), and bile acid derivatives to maximize therapeutic action at lower dosages.
We deliver customized raw material structures and complete contract manufacturing services to match the diverse demands of international markets.
Highly purified bile acid APIs, including Taurochenodeoxycholic acid and Cholic acid derivatives, conforming to international pharmacopoeia standards for therapeutic drug formulations.
Standardized botanical extracts (Olive Leaf Extract, Pueraria Lobata, Maca) in high-density powder, capsule, or tablet formats designed for clinical-grade dietary supplements.
Bioactive cellular antioxidants such as Ergothioneine and Hesperidin designed to protect skin structures against lipid peroxidation and micro-inflammatory stress.
Natural extract solutions (Yucca extract, bile acid premixes) that support livestock lipid metabolism, improve growth ratios, and optimize liver and intestinal functions.
In the post-pandemic global economy, supply chain resilience is a non-negotiable metric for global pharmaceutical and nutraceutical brands. The traditional reliance on fragmented raw material suppliers often results in regulatory discrepancies, batch-to-batch variations, and lead-time delays.
Chenlv Herb's 9,514m² modern smart facility in Chengdu, China, represents the standard of China Factory 4.0. We utilize fully automated stainless-steel extraction lines, advanced continuous countercurrent extraction technology, and closed-loop solvent recovery systems. By automating critical parameters such as temperature, pressure, flow rate, and vacuum level, we eliminate human error and achieve exceptional batch consistency.
Furthermore, our geographical placement in Southwestern China provides us with direct, sustainable access to wild and cultivated botanical reserves, securing a robust, uninterrupted supply chain of raw biomass at highly competitive cost points.
We align our industrial capacity with the operational standards required by enterprise purchasing agents and pharmaceutical buyers.
We supply complete technical dossiers including High-Performance Liquid Chromatography (HPLC) chromatograms, Gas Chromatography-Mass Spectrometry (GC-MS) profiles, and comprehensive microbiological validation to guarantee active molecule standardization.
Every shipment is accompanied by complete batch-specific Certificates of Analysis (COA), Allergen Statements, GMO-Free Declarations, and heavy metal testing results matching strict European and US FDA thresholds.
With scalable manufacturing reactors capable of handling metric tons of biomass per batch, we guarantee short lead times, competitive EXW/FOB pricing, and seamless custom clearance support for international markets.
Cardiovascular products operate under intense regulatory scrutiny. Our production environment and quality management systems are designed to meet the strict expectations of the world's most demanding regulatory bodies.
From raw material collection to final packaging, every step is traceably documented. Our processes conform fully to cGMP (Current Good Manufacturing Practice), and we maintain valid third-party certifications including ISO 9001, ISO 22000, HALAL, KOSHER, and FDA Registration. This guarantees that your ODM products can be seamlessly imported and distributed in the European Union, North America, Southeast Asia, and beyond.
Furthermore, we provide localized documentation support, assisting our international buyers in regulatory filings, dossier compilation, and structural formulation clearances.
From structural formulation concepts to global delivery, our structured timeline guarantees rapid, secure market launch.
Deep assessment of client formulation target requirements.
Custom price proposals detailing ingredient targets.
Formalizing partnership parameters and SLA safeguards.
R&D sample synthesis and structural molecular verification.
Mass scale extraction matching strict ISO/GMP regulations.
Batch verification, third-party analysis, and COA issuance.
Global logistic integration for safe delivery.
Stay updated with structural developments in raw materials, production, and international regulatory dynamics.
Recently, the market price of Citrus aurantium raw materials in China has been on the rise, drawing significant attention from the industry. As the new production season (May-June) comes to an end and new supplies gradually enter the market, price fluctuations have become a focal point due to supply and demand dynamics and cost considerations.
As a 'calling card' for leading China's pharmaceutical industry onto the global stage, the 23rd China Pharmaceutical Raw Materials Exhibition (CPHI China 2025) will join hands with the 18th China Pharmaceutical Machinery to present the latest breakthroughs in active ingredient extraction and biosimilar manufacturing.
The 92nd China International Pharmaceutical Raw Materials / Intermediates / Packaging / Equipment Fair (API China) will grandly open at the China Import and Export Fair Exhibition Hall in Guangzhou from May 21-23, 2025, detailing new trends in high-purity metabolic extraction.
Detailed technical answers to the most common queries from buyers, formulators, and regulatory experts.
We employ advanced High-Performance Liquid Chromatography (HPLC) and gas chromatography techniques to standardize our botanical extracts. For example, our Hesperidin and Berberine derivatives are standardized to precise concentration ranges (up to 98% purity). This ensures that every manufacturing batch contains the exact therapeutic concentration of active compounds required to regulate the targeted lipid pathway.
Yes. We provide complete OEM/ODM formulation services. Our specialized R&D division can design custom proprietary blends combining classic lipid regulators (such as phytosterols and red yeast rice extracts) with highly active bile acids (like Taurochenodeoxycholic acid) to address cardiovascular health through multiple biological pathways.
Our extraction lines prioritize eco-friendly physical extraction processes (such as supercritical CO2 extraction and water-based countercurrent systems). When organic solvents are required, we utilize advanced vacuum distillation to remove solvent residues. Final testing checks against USP and EP standard limits, ensuring the final powder is clean and non-toxic.
Absolutely. All our raw materials are produced in compliance with cGMP standards. We provide complete documentation support including allergen statements, heavy metal limits verification, pesticide residue tests (conforming to USP <561>), and non-GMO certification, allowing for smooth custom clearances in Western markets.
For standard catalog extracts, delivery times range from 7 to 15 days from deposit confirmation. For custom molecular modifications or OEM finished dose products (capsules/tablets), the timeframe is approximately 30 to 45 days, including structural sample matching, stability testing, and batch analysis.
Our state-of-the-art laboratory features advanced analytical equipment including HPLC, UV-Vis spectrophotometers, Atomic Absorption Spectroscopy (AAS) for heavy metal detection, and specialized microbiological incubators. Every batch must pass strict internal QC testing before receiving its official Certificate of Analysis (COA).
Discover our comprehensive range of specialized biochemicals and botanicals designed to support overall human cellular vitality and metabolic pathways.
Chenlv Herb
